Zhongyuan Xiehe announced that the VUM02 injection from its wholly-owned subsidiary Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. was used in phase I/II clinical trials of grade II to grade IV acute graft-versus-host disease where hormone treatment failed. The first phase I multiple dose subjects completed enrolment administration on July 17, 2026. As of May 2026, the project invested a total of 8.308,900 yuan in R&D. Drugs need to complete clinical trials, apply for marketing approval, and be reviewed and approved before they can be marketed. There is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.